Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

GE to Expand in Biomedical and Life Sciences with Strategic Acquisitions from Thermo Fisher Scientific

By BiotechDaily International staff writers
Posted on 15 Jan 2014
General Electric (GE; Fairfield, CT, USA) and Thermo Fisher Scientific (Waltham, MA, USA) have entered into an agreement for GE’s subsidiary GE Healthcare (Little Chalfont, UK) to acquire cell culture media and sera, gene modulation, and magnetic beads businesses from Thermo Fisher for approximately USD 1.06 billion. The three businesses to be acquired generated combined annual revenues of approximately USD 250 million in 2013.

GE Healthcare’s leadership in medical diagnostic technology includes its USD 4 billion life sciences business. The acquisition, anticipated to close in early 2014 (subject to regulatory approvals), will allow GE to expand its offering and development of technologies for the discovery and manufacturing of innovative new medicines, cell therapies, vaccines, and diagnostics in the biomedical sector of its growing life sciences division. It will also extend GE’s bioprocessing manufacturing footprint in Asia, the Americas, and Europe.

Thermo Fisher’s HyClone cell culture media and sera products are highly complementary to GE Healthcare’s established technologies for cell biology research and biopharmaceutical manufacturing, enabling GE to offer its customers a substantially wider range of technologies and services. Thermo Fisher’s gene modulation technologies complement GE’s established technologies for drug discovery research, and the Sera-Mag magnetic beads product line extends GE’s existing technologies in protein analysis and medical diagnostics. The complementary product offerings and strong strategic fit of the acquisitions will also enable GE Healthcare to expand and accelerate the development of new “end-to-end” technologies.

“Life sciences is one of our strongest and fastest-growing business areas, driven by the world’s demand for improved diagnostics and new, safer medicines. Combining GE’s engineering expertise with our capabilities in life sciences is already bringing great benefits to industry, research, and patients. This deal [...] will help us realize our vision of bringing better healthcare to more people at lower cost,” said John Dineen, president and CEO, GE Healthcare.

“We look forward to the HyClone cell culture and other businesses joining the GE family. They are a great fit with our key areas of focus, and bring exciting new technologies, enhanced manufacturing capabilities as well as a great group of talented people to help grow our business,” said Kieran Murphy, president and CEO of GE Healthcare’s life sciences division. “In addition to providing us with new approaches to drug discovery and biomedical research, this acquisition is a significant step forward for our customers in biopharmaceutical manufacturing. They will benefit immediately from an expanded range of “start-to-finish” technologies that will help them improve product yields and reduce time-to-market. By expanding our production facilities to three continents, we will be able to offer the biopharmaceutical industry greater confidence in the security of supply of cell culture media and sera.”

Related Links:
General Electric
GE Healthcare
Thermo Fisher Scientific


WATERS CORPORATION

Channels

Genomics/Proteomics

view channel
Image: Exosomes loaded with catalase (shown in red) efficiently interact with neurons (shown in black) to protect them from the effects of Parkinson\'s disease (Photo courtesy of Dr. Elena Batrakova, University of North Carolina).

Exome Delivery of the Anti-Oxidant Catalase Reduces Parkinson's Disease Symptoms in Mouse Model

The exosome delivery of the antioxidant enzyme catalase was shown to dramatically reduce symptoms of Parkinson's disease (PD) in a mouse model. Exosomes are cell-derived vesicles that are present in... Read more

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Lab Technologies

view channel
Image: The gene assembly robot, the GeneTheatre (Photo courtesy of Analytik Jena AG).

Genomic Research Laboratories Await New Compact Liquid Handling System

A small footprint benchtop liquid handler that automates multiple gene assembly tasks and associated procedures such as PCR setup is now available for use by biotech and genomic research laboratories.... Read more
 

Events

27 May 2015 - 28 May 2015
02 Jun 2015 - 03 Jun 2015
15 Jun 2015 - 18 Jun 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.